Stocks to Watch: COST, LTD, PIR, SHLD, P & More

Take a look at some of Thursday's morning movers:

Costco - The warehouse retailer reported an August same-store sales increase of 6 percent, above Street estimates of a 4.5 percent rise.

Limited Brands - Limited saw an August same-store sales rise of 8 percent versus estimates of a 4.2 percent rise.

Pier 1 Imports - The retailer is forecasting fiscal second quarter earnings slightly ahead of analyst estimates, saying customers are responding well to its new merchandise lineup.

Sears Holdings - The retailer’s shares have lost their spot in the S&P 500 index. S&P notes that Sears’ public float has been well below the 50 percent threshold required for inclusion for some time now, and will replace Sears with chemical maker LyondellBassell. Sears — in one corporate form or another — has been in the S&P 500 since it was created 55 years ago, and was in the Dow Industrials from January 1924 until November 1999.

Pandora Media - The internet music service reported a breakeven second quarter, compared to analyst estimates of a $0.03 per share loss. It also sees current quarter revenues above Wall Street’s estimates, as it moves to attract more listeners and sell more mobile ads.

TiVo - TiVo lost $0.23 per share for the second quarter, slightly smaller than the $0.24 loss analysts had been projecting. The digital video recorder maker saw continued growth in its subscriber numbers, but also reported higher expenses as well.

Vera Bradley - The company earned $0.33 per share for the second quarter, two cents below estimates, and the women’s accessories retailer also projected fiscal year earnings and revenues below Street estimates.

Barclays - The bank has picked its retail boss Antony Jenkins as its new chief executive officer, replacing Bob Diamond.

We’ll watch housing stocks like Lennar, Pulte Group , and D.R. Horton after RealtyTrac reported that the raw number of foreclosure home sales dropped 22 percent during the second quarter from a year earlier.

Teva Pharmaceutical - The drugmaker has won FDA approve to market its version of Amgen’s Neupogen a drug that boosts production of white blood cells in certain cancer patients. This drug was the subject of patent litigation with Amgen, which ended last year with an agreement by Teva to refrain from launching its version in the U.S. until November 2013.

Louisiana-Pacific has been downgraded to "hold" from "buy" at Deutsche Bank. The firm says the stock's current price represents fair value, especially given the forest products industry's "disappointing" financial record.

—By CNBC’s Peter Schacknow

Questions? Comments? Email us at [e-mail]